DuPont Launches AmberChrom™ SIL Silica Gel for Chromatography to Advance Manufacturing of GLP-1 and Other Peptide Therapeutics

DuPont (NYSE: DD) today announced the launch of DuPont™ AmberChrom™ SIL silica gel, a new reverse phase silica-based solution designed to support the purification and manufacture of peptide therapeutics, including glucagon-like peptide-1 (GLP-1) receptor agonists. The addition of AmberChrom™ SIL silica gel expands DuPont's bioprocessing purification portfolio with reverse phase silica technology designed for demanding peptide separations and final high-purity polishing.